Incidence of Tumor Growth and Tumor Regression in Athymic Mice Injected With CA46 BL Cells Alone or in Conjunction With EBV+ or EBV− BL Cells
| Cell Line . | EBV Status . | Tumors/ Mice Injected . | Days to Tumor Appearance . | Days to Tumor Regression . | Regressing Tumors . | % Regression . | Maximum Size (cm2) . |
|---|---|---|---|---|---|---|---|
| CA46 | − | 4/4 | 8.0 ± 3.4 | — | 0/4 | 0 | — |
| CA46 + PA682 BM2 | + | 4/4 | 10.0 ± 3.5 | 20 ± 5.0 | 2/4 | 50 | 3.9 ± 1.3 |
| CA46 + PA682 PB | + | 3/3 | 9.0 ± 0.0 | 37 ± 9.9 | 2/3 | 66 | 5.2 ± 2.9 |
| CA46 + PA682 PE2 | + | 3/3 | 9.0 ± 0.0 | 45 ± 15 | 3/3 | 100 | 2.5 ± 1.1 |
| CA46 + EW36 | − | 5/5 | 11 ± 0.0 | — | 0/5 | 0 | — |
| CA46 + BL41 | − | 2/2 | 12 ± 1.4 | — | 0/2 | 0 | — |
| Cell Line . | EBV Status . | Tumors/ Mice Injected . | Days to Tumor Appearance . | Days to Tumor Regression . | Regressing Tumors . | % Regression . | Maximum Size (cm2) . |
|---|---|---|---|---|---|---|---|
| CA46 | − | 4/4 | 8.0 ± 3.4 | — | 0/4 | 0 | — |
| CA46 + PA682 BM2 | + | 4/4 | 10.0 ± 3.5 | 20 ± 5.0 | 2/4 | 50 | 3.9 ± 1.3 |
| CA46 + PA682 PB | + | 3/3 | 9.0 ± 0.0 | 37 ± 9.9 | 2/3 | 66 | 5.2 ± 2.9 |
| CA46 + PA682 PE2 | + | 3/3 | 9.0 ± 0.0 | 45 ± 15 | 3/3 | 100 | 2.5 ± 1.1 |
| CA46 + EW36 | − | 5/5 | 11 ± 0.0 | — | 0/5 | 0 | — |
| CA46 + BL41 | − | 2/2 | 12 ± 1.4 | — | 0/2 | 0 | — |
BALB/C nu/nu mice were injected subcutaneously with CA46 (107 cells in 0.2 mL RPMI), either alone or mixed with 107 cells from one of five Burkitt's lymphoma cell lines (PA682 BM2, PA682 PB, PA682 PE2, EW36, or BL41). Experimental conditions and evaluation are described in the legend to Table 1.